Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + lumretuzumab + paclitaxel
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three agents: - **Carboplatin** is a platinum-based chemotherapy that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **Lumretuzumab** is a humanized monoclonal antibody targeting the HER3 (ERBB3) receptor, inhibiting its signaling and thereby blocking tumor cell growth driven by this pathway. - **Paclitaxel** is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. The combination of carboplatin and paclitaxel forms the backbone of chemotherapy for several solid tumors, including ovarian, lung, endometrial, cervical, and head & neck cancers[1][4][5][6]. Lumretuzumab has been investigated as an add-on targeted therapy in various clinical trials for HER3-expressing cancers. The rationale for combining these drugs is to leverage both cytotoxic (carboplatin/paclitaxel) and targeted (lumretuzumab) mechanisms to improve antitumor efficacy.
- Other names
- lumretuzumab + carboplatin + paclitaxel
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)DNA
Beyond the preview
Go deeper on carboplatin + lumretuzumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + lumretuzumab + paclitaxel.